Ms. Wang focuses her practice on corporate law and have extensive experience in a variety of complex cross-border transactions, including mergers and acquisitions (inbound and outbound), joint ventures, private equity investments, acquisition-related financings, and integration and management after the investment. 

She now undetakes to provide comprehensive legal support for all overseas capital markets transactions conducted by Luye, and works closely with the business development and strategic planning teams to support all these projects.

Representative Matters

 Luye Pharma Group: to participate its transaction that Luye grants AstraZeneca China an exclusive rights to promote Luye Pharma’s XueZhiKang capsules in mainland China

 Luye Pharma Group: to participate its major transaction that Luye acquires Astrazeneca’s rights relating to Seroquel and Seroquel XR in China and in other territories

 Luye Pharma Group: to participate its venture capital investment in a US fund that mainly focus on China healthcare industry

Prior to joining Luye Pharma, Ms. Wang advised in the following selected M&A transactions:

 A Shanghai entertainment company's outbound investment in a European company by acquiring a 27.9% stake

 A famous trust company’s equity acquisition of the famous mining company worth of RMB 15 billion (including 44 coal mining enterprises)

 A Shanghai public company’s equity acquisition of several technology companies located in four cities across China (including Hangzhou, Ningbo, Chengdu, Shanghai)